Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or distress. Symptoms of the disorder include a strong desire to use opioids, increased tolerance to opioids, failure to fulfill obligations, trouble reducing use, and withdrawal syndrome with discontinuation. Opioid withdrawal symptoms may include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are components of a substance use disorder. Complications may include opioid overdose, suicide, HIV/AIDS, hepatitis C, marriage problems, or unemployment.
Indivior UK Ltd., a subsidiary of Indivior PLC, is a British company located in Hull. The firm manufactures and distributes pharmaceutical products. It was founded in 2010.
Alar Pharmaceuticals, Inc.
http://www.alarpharm.com
|
Alar Pharmaceuticals, Inc. engages in the development of long-acting release drug products for CNS disorders and chronic diseases. It develops drugs for opioid use disorder, chronic pain, and major depressive disorder. The company was founded on September 23, 2016 and is headquartered in Taichung, Taiwan.
Drug
Drug product
Major depressive disorder
Chronic pain
Opioid use disorder
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential.
Their rationale for developing these medicines is based on key insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients.
They are based in New York City but have collaborators and are working with patients across the United States and the globe.
Neurology
Orphan diseases
Epilepsy
Medicine
Intellectual property
Fragile X syndrome
Clinical trial
Ivacaftor
Cystic fibrosis
Major depressive disorder
Antidepressant
Biomarker discovery
Biomedicine
Biotechnology
Sloan-Kettering Institute for Cancer Research
Janssen Pharmaceutica NV
http://www.janssen.com/belgium
|
Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.
Product design
Neuroscience
Pharmacy and Therapeutics
Neurological disorder
Mental illness
Therapeutic Area
Medicine
Biomedicine
Biotechnology
Deck
Antifungal drug
Contract research organization
Companion diagnostic
Exosome
Infection drug
Clinical research
Immunotherapy
Biophysics
Antifungal
U.S. Department of Veteran Affairs
The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.
Health Insurance Portability and Accountability Act
Wearable technology
Hennepin Healthcare Research Institute
https://www.hhrinstitute.org
|
Hennepin Healthcare Research Institute conducts medical research with the aim of improving the healthcare industry.
Pear Therapeutics (US), Inc.
http://www.peartherapeutics.com
|
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.
Software
Medical food
PEAR
Combination Product
Effective treatment
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Dosage form
Medicine
Clinical trial
Oncology
Oncology drugs
Cardiovascular agent
Monoclonal antibody
Immunotherapy
Inhaler
Adalimumab
Genomics
Bronchodilator
Rituximab
Biopharmaceutical
Dry-powder inhaler
Metered-dose inhaler
Optometry
Gastrointestinal agent
Bevacizumab
Regents of the University of California
The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).
Pathology
Companion diagnostic
Tulane Educational Fund is a private company headquartered in the United States specializing in radio broadcasting stations.
Delpor, Inc. engages in developing and acquiring drug delivery technologies that enable the sustained or pattern specific release of proteins, peptides, and small molecules through a small non-mechanical subcutaneous implant. Its technologies include Prozor, which is used for the delivery of antipsychotics and other small molecule drugs from a non-mechanical implantable drug delivery device; NANOPOR, a non-mechanical implantable drug delivery device in which sustained release is provided by membrane architecture; and Delos PUMP, a self-contained and electro-osmotically driven implantable drug delivery device to deliver drugs in predetermined patterns. The company was incorporated in 2009 and is based in San Francisco, California.
Medicine
Small molecule
Peptide
Drug development
Monoclonal antibody
Nalmefene
Transport protein
Drug
Drug discovery
Opioid use disorder
Naltrexone
Antipsychotic
Opioid antagonist
Mood stabilizer
Opioid receptor
Biotechnology
Buprenorphine
Drug-eluting stent
Antidepressant
Addiction
Genemarkers LLC
http://www.genemarkersllc.com
|
Genemarkers LLC operates as a biotechnology company. It specializes in the application of genomic science to health care, pharmaceutical research, and consumer product development. The company was founded by Anna Langerveld and is headquartered in Kalamazoo, MI.
Nexalin Technology,Inc. designs and manufactures transcranial electrical stimulation equipment to treat anxiety, insomnia, and depression. It engages in developing, building, and operating medical treatment facilities that utilize Nexalin technology, a non-invasive drugless therapy. Nexalin Technology,Inc. was founded in 2010 and is based in Irvine, California.
Anxiety
Computer hardware
Software
Medical treatment
Part of Oracle Corp., Cerner Innovation, Inc. is a company headquartered in the United States specializing in information retrieval services.
Information retrieval
Software as a service
Enterprise software
Software development
Software
People also interested in
Computer hardwarePathologyBiophysicsInformation retrievalNeuroscienceBiomedicineClinical trialExosomeFragile X syndromeNalmefene